FDA Tweaks JAK Inhibitor Indication in Inflammatory Bowel Disease

(MedPage Today) — The FDA updated the indication of the JAK inhibitor upadacitinib (Rinvoq) in inflammatory bowel disease (IBD) to account for cases where a patient may not be appropriate for a TNF blocker, drugmaker AbbVie announced on Monday…